Skip to main content

Lupus

      RT @RichardPAConway: Fava et al. Urinary biomarkers at 3 months better than UPCR in predicting 12 month treatment respon
      Fava et al. Urinary biomarkers at 3 months better than UPCR in predicting 12 month treatment response in SLE nephritis . CD163 AUC 0.83 vs 0.75 for UPCR @THKC1 @RheumNow #ACR22 Abstr#0536 https://t.co/YI3JC2uKcv https://t.co/jnkfbI0Z1M
      RT @RichardPAConway: Jorge et al. @AprilJorgeMD Incidence SLE nephritis - 16% onset, 35% 15 years. 44.7% men vs 28.6% wo
      Jorge et al. @AprilJorgeMD Incidence SLE nephritis - 16% onset, 35% 15 years. 44.7% men vs 28.6% women at 10 years. 40% Black, 38% Hispanic, 40% Asian, 23% White. @RheumNow #ACR22 Abstr#0538 https://t.co/Nbx16jZAN7 https://t.co/BEnAtbcIHt
      RT @RichardPAConway: Tofighi et al. VTE in SLE nephritis. 10% VTE, 5.2% VTE after SLE nephritis diagnosis. Risks - Black
      Tofighi et al. VTE in SLE nephritis. 10% VTE, 5.2% VTE after SLE nephritis diagnosis. Risks - Black patients, ds-DNA+, SDI, aPL+, SLEDAI. @RheumNow #ACR22 Abstr#0541 https://t.co/G6q0qvirf7 https://t.co/B8STBTMy14
      A Year in Review
      RT @RHEUMarampa: Interesting study by Dr Ai Li Yeo and colleagues on repetitive anti-dsDNA testing and flare prediction:
      2 years ago
      Interesting study by Dr Ai Li Yeo and colleagues on repetitive anti-dsDNA testing and flare prediction: 🔅Fluctuations (⬆️and ⬇️) in anti-dsDNA >2 fold was assoc'd w/⬆️flares in all groups including persistently + pts. #ACR22 @RheumNow ABST#327 https://t.co/q0WXnIwV4A
      RT @ericdeinmd: Abst0338 #ACR22 Transition from CLE to SLE
      324 cases of incident cutaneous lupus, mean f/u 8 years
      26 pt
      2 years ago
      Abst0338 #ACR22 Transition from CLE to SLE 324 cases of incident cutaneous lupus, mean f/u 8 years 26 pts developed SLE. 5.2% transition by 5 years, <3% risk every 5 yrs from 5-20 years Risk factors: SCLE, younger age, recent diagnosis @RheumNow #ACRBest https://t.co/JFcUIkfA9n